![Clinton Snow](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Clinton Snow
Direttore/Membro del Consiglio presso ICETANA LIMITED
Profilo
Clinton Snow is currently a Non-Executive Director at Dimerix Ltd., PolyActiva Pty Ltd., and iCetana Ltd.
He completed his undergraduate degree at the University of Melbourne.
Posizioni attive di Clinton Snow
Società | Posizione | Inizio |
---|---|---|
ICETANA LIMITED | Direttore/Membro del Consiglio | 08/02/2022 |
DIMERIX LIMITED | Direttore/Membro del Consiglio | 01/05/2023 |
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Direttore/Membro del Consiglio | - |
Formazione di Clinton Snow
University of Melbourne | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ICETANA LIMITED | Technology Services |
DIMERIX LIMITED | Health Technology |
Aziende private | 1 |
---|---|
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Borsa valori
- Insiders
- Clinton Snow